Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Assets (2022 - 2025)

Atara Biotherapeutics' Current Assets history spans 4 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Current Assets fell 81.18% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, down 81.18%, while the annual FY2025 figure was $12.2 million, 81.18% down from the prior year.
  • Current Assets reached $12.2 million in Q4 2025 per ATRA's latest filing, down from $18.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $347.0 million in Q2 2022 to a low of $12.2 million in Q4 2025.
  • Average Current Assets over 4 years is $141.5 million, with a median of $104.2 million recorded in 2023.
  • Peak YoY movement for Current Assets: decreased 22.61% in 2024, then crashed 81.18% in 2025.
  • A 4-year view of Current Assets shows it stood at $295.1 million in 2022, then plummeted by 65.48% to $101.9 million in 2023, then tumbled by 36.3% to $64.9 million in 2024, then plummeted by 81.18% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Current Assets are $12.2 million (Q4 2025), $18.4 million (Q3 2025), and $24.8 million (Q2 2025).